Rituximab administered as induction or maintenance therapy in combination with
cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly prolonged …

The aim of this prospective, single-arm study was to test the efficacy and tolerability of
autologous stem cell transplantation (auto-SCT) combined with in vivo rituximab purging …

Salvage chemotherapy followed by high-dose therapy and autologous stem cell
transplantation is the standard of treatment for chemosensitive relapses in diffuse large B …

Background: Rituximab in combination with cyclophosphamide, doxorubicin, vincristine, and
prednisone (CHOP) significantly prolonged event-free survival in first-line chemotherapy for …

The addition of rituximab (R) to CHOP (cyclophosphamide, doxorubicin, vincristine,
prednisone) chemotherapy was a milestone in the development of front‐line therapy for …

The addition of rituximab to systemic chemotherapy has improved the response rates,
progression-free survival, and overall survival of patients with newly diagnosed diffuse large …

Rituximab‐containing salvage chemotherapy followed by high‐dose therapy and
autologous stem cell transplant (ASCT) in chemosensitive patients remains the standard of …

Objective: Patients with relapsed diffuse large B-cell lymphoma (DLBCL) who are either not
suitable for stem cell transplantation or suffer from relapsed disease after standard second …

Purpose Salvage chemotherapy followed by high-dose therapy and autologous stem-cell
transplantation (ASCT) is the standard treatment for relapsed diffuse large B-cell lymphoma …

Despite recent major advances in treating diffuse large B-cell lymphoma with dose-intense
regimens and the addition of the anti-CD20 monoclonal antibody rituximab, a significant …